Horizon Therapeutics focuses on the development of prescription drugs for mild to moderate pain relief and arthritis.
Horizon Therapeutics operates as a biopharmaceutical company. It focuses on the development of prescription drugs for mild to moderate pain relief and arthritis. The company's product candidates include HZT-501, a proprietary fixed-dose combination formulation of NSAID and ibuprofen; and HZT-602, a combination oral drug product consisting of naproxen and famotidine.Horizon Therapeutics is based in Northbrook, Illinois, and was founded in 2005.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Aug 6, 2020 | Post-IPO Equity | $0.96B | — | — | — | Detail |
Jul 11, 2019 | Post-IPO Debt | $600M | — | — | — | Detail |
Mar 6, 2019 | Post-IPO Equity | $344.99M | — | — | — | Detail |
Mar 4, 2019 | Post-IPO Equity | $326.80M | — | — | — | Detail |
Oct 20, 2016 | Post-IPO Debt | $300M | — | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Deepfield | Yes | Post-IPO Debt |
Essex Woodlands Healthcare Partners | Yes | Series C |
Scale Venture Partners | Yes | Series B |
Citigroup Global Markets | — | Post-IPO Debt |
Cowen and Company | — | Post-IPO Debt |
Kreos Capital | — | Post-IPO Debt |
Oxford Finance LLC | — | Post-IPO Debt |
Silicon Valley Bank | — | Post-IPO Debt |
Pequot Capital | — | Series C |
Sutter Hill Ventures | — | Series C |
Horizon Pharma has acquired 7 organizations. Their most recent acquisition was Nitec Pharma AG on Apr 1, 2010. They acquired Nitec Pharma AG for 0.
Date
Company Name
|
Industry | Acquisition Type | Price | |
---|---|---|---|---|
Apr 1, 2010
Nitec Pharma AG
|
Biotechnology | merge | — | Detail |
Mar 19, 2014
Vidara Therapeutics
|
Biotechnology | — | — | Detail |
Mar 30, 2015
Hyperion Therapeutics
|
Biopharma | acquisition | $ 1.10B | Detail |
Sep 12, 2016
Raptor Pharmaceuticals
|
Biopharma | acquisition | $ 800M | Detail |
May 8, 2017
River Vision Development
|
Health Care | acquisition | $ 145M | Detail |